Cagrilintide and tirzepatide are both once-weekly injections studied for weight, but they work through different hormone systems and sit at different regulatory stages. Cagrilintide is an amylin analog, tirzepatide is a GLP-1/GIP incretin, and only tirzepatide is FDA-approved, so the evidence behind each is not on equal footing.
Reviewed for accuracy · Last reviewed July 8, 2026The clearest practical difference is regulatory. Tirzepatide has an approved label, a defined titration, and Phase 3 evidence, whereas cagrilintide is investigational: its monotherapy human evidence comes from a Phase 2 dose-finding trial, with Phase 3 data centered on the semaglutide combination (CagriSema) rather than cagrilintide alone.
Mechanistically these are different kinds of drug. Cagrilintide mimics amylin, a hormone that signals fullness and slows gastric emptying, while tirzepatide acts on the GLP-1 and GIP incretin receptors. Because they target separate pathways, cagrilintide has been studied paired with a GLP-1 drug rather than as a direct incretin substitute. Whether either approach is preferable in practice is not something the current evidence lets anyone state as fact.
Both were studied as once-weekly subcutaneous injections with gradual dose escalation, and both reported predominantly dose-related gastrointestinal side effects such as nausea. Neither of these summaries is a substitute for medical advice about which, if either, is appropriate.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.